| Class | Thrombolytic agent |
|---|---|
| Chemistry |
Recombinant protein
|
| Routes of administration |
IV or intraarterial |
| Absorption |
Zero oral bioavailability
|
| Solubility |
pKa 6.25; good water solubility
|
| Distribution |
VOD = 0.07L/kg (effectively confined to the circulating volume); minimally protein bound
|
| Metabolism |
Metabolised by the liver, most likely by the reticuloendothelial system
|
| Elimination |
Minimal renal excretion
|
| Time course of action |
Initial half life ~ 5 minutes; eliminaton half life 72 minutes
|
| Target receptor |
Plasminogen-fibrin complex |
| Mechanism of action |
Serum protease which has specific affinity for plasminogen in the presence of fibrin. Catalyses the conversion of plasminogen to plasmin, which degrades fibrin strands |
| Clinical effects |
Thrombolytic effect extends into bleeding complications, which can be very serious. Anaphylaxis is not unknown, given that this is a recombinant protein |
| Literature reference |
TGA PI document |
| CICM details of understanding | Level 3 |
| Mentioned around Deranged Physiology | |
| Related SAQs |
Question 4 from the first paper of 2013 Second part exam: Question 16 from the second paper of 2015 Question 4 from the first paper of 2001 |